DOCSLIB.ORG

Determination of Some Beta Adrenergic Agonists Using Different Spectroscopic and Electrochemical Techniques

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Determination of Some Beta Adrenergic Agonists Using Different Spectroscopic and Electrochemical Techniques Determination of Some Beta Adrenergic Agonists Using Different Spectroscopic and Electrochemical Techniques A Thesis Presented by Marwa Mohamed Abdelmonem Sakr B. Pharm. Sci. (2002) Faculty of Pharmacy, Helwan University M. Pharm. Sci. (2010) Faculty of Pharmacy and Biotechnology, German University in Cairo Submitted for The Degree of Doctor of Philosophy in Pharmaceutical Sciences (Pharmaceutical Chemistry) Supervised by Professor Dr. Samir Mohamed El-Moghazy Professor of Pharmaceutical Chemistry Faculty of Pharmacy Cairo University Professor Dr.Hala Sultan Al-Easa Professor of Organic Chemistry Faculty of Arts and Sciences Qatar University Dr.Marwa Ahmed Fouad Associate Professor of Pharmaceutical Chemistry Faculty of Pharmacy Cairo University Dr.Rasha Sayed Hanafi Associate Professor of Pharmaceutical Chemistry Faculty of Pharmacy and Biotechnology German University in Cairo Faculty of Pharmacy Cairo University 2018 Abstract CHAPTER ONE I. INTRODUCTION In this section, a detailed description of three fluoroquinolones and their types as well as their pharmacological mode of action is defined.. CHAPTER TWO II. LITTERATURE SURVEY It delineates the chemical and physical characteristics, pharmacological actions as well as the techniques of analysis that were previously reported for the determination of norfloxacin, levofloxacin and lomefloxacin. CHAPTER THREE III. EXPERIMENTAL, RESULTS, DISCUSSIONS AND CONCLUSIVE REMARKS III.I. Spectrophotometry III.I.A. Spectrophotometry Experimental It encompasses the materials, reagents, instruments, software used as well as the experimental techniques applied. III.I.B. Spectrophotometry Results and Discussions The interaction of the three fluoroquinlones with lanthanides based on the antenna effect theory was verified and spectrofluorimetrically. III.I.C. Spectrophotometry Conclusive Remarks It entitles a general outline about results obtained in the spectrofluorimetry section. III.II. Spectrofluorimetry III.II.A. Spectrofluorimetry Experimental It includes the materials, reagents, instruments, software used as well as the experimental techniques instigated. III.II.B. Spectrofluorimetry Results and Discussions This section provides a comprehensive enlightenment about the obtained chemometric determination of the spectrophotometrically analyzed complexes. III.II.C. Spectrofluorimetry Conclusive Remarks It provides a general conclusion on the results obtained in the spectrophotometric section. III.III. Potentiometry III.III.A. Potentiometry experimental It presents the materials, reagents and instruments as well as the experimental techniques applied for the determination of norfloxacin, levofloxacin and lomefloxacin III.III.B. Potentiometry Results and discussion Electrodes were prepared and investigated for norfloxacin, levofloxacin and lomefloxacin based on the incorporation of the Tetraphenyl borate (TPB) as an ion- exchanger in PVC matrix using DOP as plasticizer III.III.C. Potentiometry Conclusive Remarks This section ends with a conclusion on the obtained potentiometric results. The thesis ends with 416 references that were of great help to the authoress. INTRODUCTION Adrenergic drug agonists Adrenergic drugs are crucial sympathomimetic agents that serve as analogues of epinephrine (adrenaline), norepinephrine (noradrenaline) and dopamine hormones secreted by the adrenal gland. They resemble these hormones not only in terms of pharmacological actions but also due to their possession of the vital catecholamine functional group. The term adrenergic literally means closely associated with adrenaline (epinephrine) and/or noradrenaline (norepinephrine) . The principle role of the stated hormones is to adapt the body to stressful conditions . When circulating in the blood, their half-life lasts for few minutes, after which they are metabolized either by catechol-O-methyl transferases or by monoamine oxidase .In other words, the pharmacological impacts exhibited by adrenergic drug agonists contributes to the effectual activation of adrenergic receptors. Adrenergic receptors are divided into two categories α and β (α1, α2, β1, and β2 receptors) by which adrenergic drugs exert their pivotal effects. α –receptors are mainly activated by norepinephrine while β receptors are primarily activated by epinephrine, however epinephrine may also activate α receptors. Adrenergic drug agonists are divided into three classes: direct acting, indirect acting, and dual acting . I.II. Classification of β – Adrenergic drug agonists I.II.A. β1-Receptor activating drugs Due to their prevalence in the heart muscle and kidney, β1- are largely associated with the conducting system (e.g., pacemaker) and the ventricular musculature. They are also abundant in sweat and salivary glands. Epinephrine or norepinephrine cause excitatory responses in these tissues. Activation of β1 receptors in the heart has a positive inotropic effect leading to an increase in the force of contraction, thus improving cardiac performance. I.II.B. β2 –Receptor activating drugs β2 Receptors are mostly present in bronchial smooth muscle and blood vessels of skeletal muscle. They can also be found in arterioles, heart, lung, uterus, and liver. Therapeutic applications of β2 stimulation are restricted to the lungs and the uterus. The key role of β2-adrenergic drug agonists, is to cause smooth muscle relaxation in the lung promoting bronchodilation , thus relieving or preventing asthma attacks. Accordingly, these drugs serve as suitable candidates for the treatment of bronchial asthma, chronic bronchitis, emphysema and in cases of premature labor for relaxing uterine smooth muscle. An example of a β2-receptor activating drug is hexoprenaline Trivalent Lanthanides and Lanthanide-catecholamine complexes Owing to their extraordinarily high sensitivity and selectivity , as reported by literature, lanthanide III metals were known to play fundamental roles as luminescent probes in many pharmaceutical and bioanalytical applications. Lanthanide-sensitized luminescence present wide Stokes shift , narrow emission bands along with extended luminescence lifetimes . Owing to their strong emission peaks (<10 nm full width at half-maximum) in the visible and near-infrared region under UV excitation , lanthanide complexes’ luminescence has gained a lot of attention in the past decade . Attributable to their photo-transfiguration properties, these complexes are also pertinent in many other diverse fields . Aim of work Applying a multivariate approach, a chemometric-assisted spectrofluorimetric and spectrophotometric techniques were executed for the determination of Dobutamine (DOB), Hexoprenaline (HEX) and Isoprenaline (ISO) catecholamine drugs in their pure and pharmaceutical dosage forms. Predicated on the existent “antenna” interaction between the catecholamine drugs and the designated lanthanide metals, nine new chemosensors were modeled for the analysis. Lanthanum, Samarium and Terbium metals were selected for the attainment of the designated models through their complexation reactions with DOB, HEX and ISO. Four continuous factors were screened namely, reaction time (RT), metal volume (MV), temperature (T) and pH by aid of Plackett-Burman Design. Optimization for the screened factors was carried out by means of Box-Behnken Design and Central Composite Design for spectrofluorimetric and spectrophotometric techniques, respectively. The present work also aimed to offer three new ion-selective electrodes of the plastic membrane type for the determination of dobutamine hydrochloride (DOB), hexoprenaline sulphate (HEX) and isoprenaline hydrochloride (ISO) in pure and pharmaceutical dosage forms. These electrodes depend mainly on the incorporation of the ion- exchangers of the above mentioned drugs with phosphomolybdic acid (PMA) in a PVC matrix. Electrodes’ performance characteristics were tested by investigating the effects of membrane composition, soaking, temperature and pH. Selectivity of the three electrodes towards their respective ions was also examined in presence of various cations and sugars. Review Spectrofluorimetric Analysis Spectral characteristics Using the spectrofluorimetric technique, maximum fluorescence intensity was detected for the formed complexes. Ln complexes were produced at λex/λem= 312 /455 for DOB-Ln, 310/455 for HEX-Ln and 315/455 for ISO-Ln. For Sm, complexes were obtained at λex/λem= 312 /450 for DOB-Sm, 310/450 for HEX-Sm and 315/450 for ISO-Sm. Tb complexes were produced at λex/λem= 312 /550 for DOB-Tb, 310/550 for HEX-Tb and 315/550 for ISO-Tb. Thus, signifying the antenna effect phenomena through interaction between the catecholamine ligands and the three lanthanides [396]. In order to avoid direct excitation of lanthanide metals, it is worth noting that excitation peaks were carefully chosen at these given wavelengths. Figs. 6-8 demonstrates the excitation and emission spectra for the three blank catecholamines and their spectra after complexation with Ln3+, Sm3+, Tb3+, respectively. Experimental Designs Screening step using Plackett-Burman Design (PBD) In the current work, four chief factors were studied by using a Plackett-Burman Design (PBD) with the aim of constructing the design and screening a set of experiments [87].The design included two levels for each factor with their upper (+) and lower (-) limits being adjusted. Examination of the four factors, namely reaction time (RT), metal volume (MV), temperature (T) and pH for DOB, HEX and ISO lanthanide complexes was carried out and the resultant responses were measured
Load more

Recommended publications
  • 18 December 2020 – to Date)
    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
    [Show full text]
  • Hexoprenaline: Β-Adrenoreceptor Selectivity in Isolated Tissues from the Guinea-Pig
    Clinical and Experimental Pharmacology and Physiology (1975) 2, 541-547. Hexoprenaline: p-adrenoreceptor selectivity in isolated tissues from the guinea-pig Stella R. O’Donnell and Janet C. Wanstall Department of Physiology, University of Queenstand, Brisbane, Australia (Received 12 March 1975; revision received 22 April 1975) SUMMARY 1. A catecholamine P-adrenoreceptor agonist, hexoprenaline, was examined in vitro on five guinea-pig tissues and its potency relative to isoprenaline (as 100) obtained. 2. Hexoprenaline clearly delineated between those tissues classified as containing P,-adrenoreceptors (trachea, hind limb blood vessels and uterus; relative potencies 219, 110 and 76 respectively) and those classified as containing P,-adrenoreceptors (atria and ileum; relative potencies 3.3 and 1.0 respectively). 3. Hexoprenaline differed from some previously studied noncatecholamine P-adrenoreceptor agonists in being only two-fold less potent, relative to isoprena- line, as a vasodilator in perfused hind limb than as a tracheal relaxant. Key words : j3-adrenoreceptors, blood vessels, bronchodilators, guinea-pig, hexo- prenaline, selectivity, trachea. INTRODUCTION In a previous study using in vitro preparations from the guinea-pig, O’Donnell & Wanstall (1974a) examined potential sympathomimetic bronchodilator compounds for their potency as tracheal relaxants (p,-adrenoreceptors), atrial stimulants (P,-adrenoreceptors) and vasodilators in the perfused hind limb (p2-adrenoreceptors). Some resorcinolamines showed selectivity for trachea compared with not only atria but also blood vessels. There is some evidence in dogs in vivo that other noncatecholamines, namely carbuterol (Wardell et al., 1974), and salbutamol and terbutaline (Wasserman & Levy, 1974), display similar select- ivity. If selectivity between respiratory and vascular smooth muscle represents selectivity at the p-adrenoreceptor level, it poses the question whether the P1/p2subclassification (Lands et al., 1967a; Lands, Luduena & Buzzo, 1967b) is too rigid.
    [Show full text]
  • 100 Storage Condition=50 C/Ambrh
    USOO595.5058A United States Patent (19) 11 Patent Number: S.9SS,0589 9 Jager et al. (45) Date of Patent: Sep. 21,9 1999 54). STABILIZED MEDICINAL AEROSOL 56) References Cited SOLUTION FORMULATIONS CONTAINING U.S. PATENT DOCUMENTS IPRATROPIUM BROMIDE a 5,118,494 6/1992 Schultz et al. ............................ 424/45 75 Inventors: Paul Donald Jager, Waterbury; Mark 5,190,029 3/1993 Byron et al. ... ... 128/200.14 James Kontny, New Milford, both of 5,225,183 7/1993 Purewal et al. ........................... 424/45 Conn.; Jurgen Hubert Nagel 5.439,670 8/1995 Purewal et al. ... 424/45 Ingelheim/Rhein, Germany s 5,605,674 2/1997 Purewal et al. ........................... 424/45 FOREIGN PATENT DOCUMENTS 73 Assignee: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, 0372 777 6/1990 European Pat. Off.. Conn. Primary Examiner Raj Bawa Attorney, Agent, or Firm Morgan & Finnegan, LLP 21 Appl.pp No.: 08/843,180 57 ABSTRACT 22 Filed: Apr. 14, 1997 Stabilized medicinal aeroSol Solution formulations compris O O ing medicaments that degrade or decompose by interaction Related U.S. Application Data with solvents or water, an HFC propellant, a cosolvent and an acid are described. Further, Specific medicinal aeroSol 63 Staggypt.NE "A iGs Solution formulations comprising ipratropium bromide or No. 08/153.549, Nov. 22, 1993, abandoned E. is a fenoterol, ethyl alcohol, 1,1,1,2-tetrafluoroethane or 1,1,1, continuation-in-part of application No. 07/987,852, Dec. 9, 2,3,3,3-heptafluoropropane, and either an inorganic acid or 1992, abandoned. an organic acid are described. The acids are present in 51 Int.
    [Show full text]
  • Addition of Intravenous Beta2-Agonists to Inhaled Beta2- Agonists for Acute Asthma (Review)
    Addition of intravenous beta2-agonists to inhaled beta2- agonists for acute asthma (Review) Travers AH, Milan SJ, Jones AP, Camargo Jr CA, Rowe BH This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 12 http://www.thecochranelibrary.com Addition of intravenous beta2-agonists to inhaled beta2-agonists for acute asthma (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 5 OBJECTIVES ..................................... 5 METHODS ...................................... 5 RESULTS....................................... 7 Figure1. ..................................... 8 Figure2. ..................................... 9 Figure3. ..................................... 10 DISCUSSION ..................................... 12 AUTHORS’CONCLUSIONS . 12 ACKNOWLEDGEMENTS . 13 REFERENCES ..................................... 13 CHARACTERISTICSOFSTUDIES . 19 DATAANDANALYSES. 31 Analysis 1.1. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 1 Admissions. 31 Analysis 1.2. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 2 Length of stay. 32 Analysis 1.3. Comparison 1 IV + inhaled beta agonist vs. inhaled beta-agonist, Outcome 3 Pulse rate at 2
    [Show full text]
  • 210428Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 210428Orig1s000 OTHER REVIEW(S) DIVISION OF CARDIOVASCULAR AND RENAL PRODUCTS Regulatory Project Manager Overview I. GENERAL INFORMATION NDA: 210428 Drug: Metoprolol Succinate Extended-Release Capsules, 25 mg, 50 mg, 100 mg and 200 mg Class: Beta- Blocker Applicant: Sun Pharmaceutical Industries Limited Proposed Indications: Hypertension, Angina Pectoris & Heart Failure Date of submission: March 30, 2017 PDUFA date: January 30, 2018 II. REVIEW TEAM Office of New Drugs, Office of Drug Evaluation I: Division of Cardiovascular & Renal Product Norman Stockbridge, MD, PhD, Director Mary Ross Southworth, PharmD, Deputy Director for Safety Michael Monteleone, MS, RAC, Assistant Director for Labeling Martina Sahre, PhD, Cross Discipline Team Leader Fortunato Senatore, MD, Clinical Reviewer Albert DeFelice, PhD, Non-Clinical Supervisor Muriel Saulnier, PhD, Non-Clinical Reviewer Edward Fromm, RPh, RAC, Chief, Project Management Staff Maryam Changi, PharmD, Regulatory Project Manager Office of Pharmaceutical Quality: Wendy Wilson-Lee, PhD, Application Technical Lead Grafton Adams, Regulatory Business Process Manager Milton Sloan, PhD, Drug Product Reviewer Rohit Tiwari, PhD, Drug Substance Reviewer Ben Stevens, PhD, Drug Substance Team Leader Kaushal Dave, PhD, Biopharmaceutical Reviewer Wu, Ta-Chin, PhD, Biopharmaceutical Team Leader Viviana Matta, PhD, Facility Reviewer Ruth Moore, PhD, Facility Team Leader Chunsheng Cai, PhD, Process Reviewer NDA 210428 RPM review Page 1 Reference ID: 42132034213643 Labeling/PMC-PMR to Sponsor: November 30, 2017 PDUFA Date: January 30, 2018 (Standard, 10-Month) PDUFA Goal Date: January 30, 2018 Approval letter: January 26, 2018 7. Reviews a) Divisional Memorandum: (January 26, 2018) Dr. Stockbridge indicated his concurrence on Dr. Sahre’s CDTL memo.
    [Show full text]
  • An Update on Chronic Obstructive Pulmonary Disease
    South African Family Practice 2016; 58(3):6-12 S Afr Fam Pract Open Access article distributed under the terms of the ISSN 2078-6190 EISSN 2078-6204 Creative Commons License [CC BY-NC-ND 4.0] © 2016 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0 REVIEW An update on chronic obstructive pulmonary disease Natalie Schellack,1 Gustav Schellack,2 Richard Omoding1 1Department of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University 2Pharmaceutical Industry Corresponding author, email: [email protected] Abstract Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide. It is a chronic condition which affects the respiratory system and worsens over time. Cigarette smoking and advancing age are the two major risks associated with this disease. It is concerning that the global incidence of this chronic illness is on the rise. Current projections indicate that it will become the third leading cause of death by the year 2020. Inflammatory changes underlie the pathophysiology of COPD. Irreversible damage and progressive narrowing of the air passages follow. COPD is characterised by the progressive loss of lung function. In addition, the Global Initiative for Chronic Obstructive Lung Disease released the latest update on its global strategy for the diagnosis, management, and prevention of COPD in 2015. This article provides an overview of the causative risk factors, underlying disease process, pathophysiological changes, and the classification and management of COPD, including the latest perspectives on this highly prevalent condition. Keywords: chronic bronchitis, chronic obstructive pulmonary disease, COPD, emphysema, LABA, SABA, SAMA, LAMA, methylxanthines Introduction Aetiology and pathogenesis Chronic obstructive pulmonary disease (COPD) is a leading cause of death worldwide.
    [Show full text]
  • Action of the Oxedrine and Tolazoline in Alpha-Adrenergic Receptor At
    Islami et al., 1:4 http://dx.doi.org/10.4172/scientificreports.235 Open Access Open Access Scientific Reports Scientific Reports Research Article OpenOpen Access Access Action of the Oxedrine and Tolazoline in Alpha-Adrenergic Receptor at Patients with Increased Bronchial Reactibility Hilmi Islami1*, Mehmedali Azemi2, Emir Behluli3, Feim Haliti4, Arta Dauti4, Shpend Dragusha4 and Bedri Abdullahu4 1Department of Pharmacology, Faculty of Medicine, University of Prishtina, Clinical Centre, Prishtina, Kosova 2Department of Pediatric, Faculty of Medicine, University of Prishtina, Clinical Centre, Prishtina, Kosova 3Department of Pediatric, Faculty of Medicine, University of Prishtina, Clinical Centre, Prishtina, Kosova 4Department of Pharmacy, Faculty of Medicine, University of Prishtina, Clinical Centre, Prishtina, Kosova Abstract Objective: In this work, effect of Oxedrine stimulation in alpha1 adrenergic receptor and the effect of Tolazoline as a blocker of alpha2 adrenergic receptor in patients with increased bronchial reactibility of respiratory ways were studied. Methods: Parameters of the lung function were determined by Body plethysmography. Raw and ITGV were registered and SRaw was calculated as well. Aerosolization is done with standard aerosolizing machine - Asema. Patients, in order to make a detailed study, were divided in two groups: middle reactor and severe reactor. Results: Results obtained from this research, show that stimulation of alpha1 adrenergic receptor with Oxedrine tartrate (120 mg-aerosol) caused an increase of
    [Show full text]
  • List Item Short-Acting Beta-Agonists Article-31 Referral
    Annex II Scientific conclusions and grounds for revocation or variation as applicable to the terms of the marketing authorisations and detailed explanation for the differences from the PRAC recommendation 19 Scientific conclusions and grounds for revocation or variation as applicable to the terms of the marketing authorisations and detailed explanation for the differences from the PRAC recommendation The CMDh considered the below PRAC recommendation dated 5 September 2013 with regards to the terbutaline, salbutamol, hexoprenaline, ritodrine, fenoterol and isoxsuprine containing medicinal products: 1. Overall summary of the scientific evaluation of terbutaline, salbutamol, hexoprenaline, ritodrine, fenoterol and isoxsuprine containing medicinal products by PRAC (see Annex I) On 27 November 2012, further to evaluation of data resulting from pharmacovigilance activities, Hungary informed the European Medicines Agency, pursuant to Article 31 of Directive 2001/83/EC, of their consideration that the risk-benefit balance of short-acting beta-agonists (SABAs) containing medicinal products authorised in obstetric indications has become unfavourable, taking into account the cardiovascular events reported. Hungary considered it was in the interest of the Union to refer the matter to the PRAC and expressed concerns with regards to the posology and warnings reflected in the product information. The short-acting beta-agonists (SABAs) (also known as beta-mimetics), salbutamol, terbutaline, fenoterol, ritodrine, hexoprenaline and isoxsuprine are all nationally authorised and have been on the market within the EU since the 1960s. Authorised obstetric indications for SABAs differ across Member States. The authorised obstetric indications include partus prematurus, tocolysis (for some products use is restricted to particular weeks of gestation but for others no specific gestation period is specified), external cephalic version (ECV), and hyper-uterine contractility.
    [Show full text]
  • Assessment Report for Short Acting Beta Agonists (Sabas) Containing Medicinal Products Authorised in Obstetric Indications
    23 October 2013 EMA/664276/2013 Assessment report for Short Acting Beta Agonists (SABAs) containing medicinal products authorised in obstetric indications Procedure under Article 31 of Directive 2001/83/EC INN/active substance: terbutaline, salbutamol, hexoprenaline, ritodrine, fenoterol, isoxsuprine Procedure number: EMEA/H/A-31/1347 Assessment Report as adopted by PRAC with all the information of a confidential nature deleted. 7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8416 E -mail [email protected] Website www.ema.europa.eu An agency of the European Union © European Medicines Agency, 2013. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 3 2. Scientific discussion ................................................................................ 3 2.1. Clinical aspects .................................................................................................... 4 2.1.1. Safety .............................................................................................................. 4 2.1.2. Efficacy ............................................................................................................ 8 2.2. Risk minimisation activities .................................................................................. 13 2.3. Product information ...........................................................................................
    [Show full text]
  • Pharmacology for Students of Bachelor's Programmes at MF MU
    Pharmacology for students of bachelor’s programmes at MF MU (special part) Alena MÁCHALOVÁ, Zuzana BABINSKÁ, Jan JUŘICA, Gabriela DOVRTĚLOVÁ, Hana KOSTKOVÁ, Leoš LANDA, Jana MERHAUTOVÁ, Kristýna NOSKOVÁ, Tibor ŠTARK, Katarína TABIOVÁ, Jana PISTOVČÁKOVÁ, Ondřej ZENDULKA Text přeložili: MVDr. Mgr. Leoš Landa, Ph.D., MUDr. Máchal, Ph.D., Mgr. Jana Merhautová, Ph.D., MUDr. Jana Pistovčáková, Ph.D., Doc. PharmDr. Jana Rudá, Ph.D., Mgr. Barbora Říhová, Ph.D., PharmDr. Lenka Součková, Ph.D., PharmDr. Ondřej Zendulka, Ph.D., Mgr. Markéta Strakošová, Mgr. Tibor Štark, Jazyková korektura: Julie Fry, MSc. Obsah 2 Pharmacology of the autonomic nervous system ........................................................................ 10 2.1 Pharmacology of the sympathetic nervous system ................................................................... 10 2.1.1 Sympathomimetics ............................................................................................................... 12 2.1.2 Sympatholytics ..................................................................................................................... 17 2.2 Pharmacology of the parasympathetic system ......................................................................... 19 2.2.1 Cholinomimetics .................................................................................................................. 20 2.2.2 Parasympathomimetics ......................................................................................................... 21 2.2.3 Parasympatholytics ..............................................................................................................
    [Show full text]
  • PRAC Minutes July 2013
    5 September 2013 EMA/575955/2013 Rev. 2 Pharmacovigilance Risk Assessment Committee (PRAC) Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of the 8-11 July 2013 meeting Chair: June Raine – Vice-Chair: Almath Spooner Explanatory notes The notes give a brief explanation of relevant minutes items and should be read in conjunction with the minutes. EU Referral procedures for safety reasons: Urgent EU procedures and Other EU referral procedures (Items 2 and 3 of the PRAC agenda) A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the European Union (EU). For further detailed information on safety-related referrals please see: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000150.jsp&mid =WC0b01ac05800240d0 Signals assessment and prioritisation (Item 4 of the PRAC Minutes) A safety signal is information on a new or incompletely documented adverse event that is potentially caused by a medicine and that warrants further investigation. Signals are generated from several sources such as reports of adverse events from healthcare professionals or patients (so called spontaneous reports), clinical studies and the scientific literature. The evaluation of safety signals is a routine part of pharmacovigilance and is essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine’s benefits and risks. The presence of a safety signal does not mean that a medicine has caused the reported adverse event.
    [Show full text]
  • Drugs/Medications Known to Cause Hyperhidrosis Certain Prescriptions
    Drugs/Medications Known to Cause Hyperhidrosis Certain prescriptions and non-prescription medications can cause hyperhidrosis (excess perspiration or sweating) as a side effect. A list of potentially sweat-inducing medications is provided below. Medications are listed alphabetically by generic name. U.S. brand names are given in parentheses, if applicable. This list is provided as a resource and a service. It is not exhaustive and is in no way meant to replace consultation with a medical professional. Although sweating is a known side effect of the medications listed below, in most cases only a small percentage of people using the medicines experience undue sweating (in some cases less than 1%). Medications noted with an “*” and in bold are the most likely to cause sweating and the frequency of sweating as a side effect from these medications may be as high as 50%. Medications noted with an “†” are commonly-prescribed drugs; and those with a “P” are often used for pediatrics. Key: */Bold -- Known to commonly cause hyperhidrosis † -- Commonly-prescribed drugs P -- Pediatric use Abciximab (ReoPro®) Acamprosate (Campral®) Acetaminophen and Tramadol (Ultracet™) Acetophenazine (NA) Acetylcholine (Miochol-E®) P Acetylcysteine (Acetadote®) P Acitretin (Soriatane®) Acrivastine and Pseudoephedrine (Semprex®-D) † Acyclovir (Zovirax®) P Adenosine (Adenocard®; Adenoscan®) † Albuterol (Proventil® HFA Inhalation Aerosol) Alemtuzumab (Campath®) Alizapride (NA) Almotriptan (Axert™) Alosetron (Lotronex®) Amonafide (NA) Ambenonium (Mytelase®) Amitriptyline
    [Show full text]